http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Weijing Zhao,Xinyan Xiao,Zhihao Ye 한국섬유공학회 2021 Fibers and polymers Vol.22 No.2
Flame-retardant SiO2/APP@PDMS fabric with superhydrophobicity was prepared via ultrasound-assisted sol-gelmethod and dip-coatings, in which cotton fabric was substantially decorated with amino functionalized SiO2 (SiO2-NH2),ammonium polyphosphate (APP) and polydimethylsiloxane (PDMS). The surface morphology, element composition andfunctional groups were examined by SEM, EDS and ATR-FTIR, respectively. The SiO2/APP@PDMS fabric exhibited selfcleaningproperty to the solid and liquids with water contact angle (WCA) around 154 °, and showed high separationefficiency for n-dodecane (98.5 %) and n-hexane (96 %), which maintained stable after 10 separation cycles. Furthermore,the SiO2/APP@PDMS fabric presented a lower mass loss rate from TGA curve, indicating the improved thermal stability. The synergistic effect of PDMS and APP resulted in the excellent flame-retardant property of the SiO2/APP@PDMS fabric,during which the dense intumescent char layer formed and the fabric extinguished immediately. The SiO2/APP@PDMSfabric with facile fabrication process exhibited potential applications for both oil/water separation and flame-retardant areas.
Comprehensive approach to controlling chronic hepatitis B in China
Shan Shan,Xinyan Zhao,Jidong Jia 대한간학회 2024 Clinical and Molecular Hepatology(대한간학회지) Vol.30 No.2
Hepatitis B virus (HBV) infection was highly endemic in China, where the prevalence of HBsAg was 9.7% in 1992. Comprehensive strategies, including universal infant hepatitis B vaccination with emphasis on timely birth-dose and 3-dose coverage, dramatically reduced the mother-to-infant transmission and early childhood acquisition of HBV, resulting in estimated HBsAg prevalence rates of 5.6% and 0.1% in the general population and among children aged <5 years in 2022, respectively. Clinical guidelines on the prevention and treatment of chronic hepatitis B have been periodically updated based on emerging evidence from clinical research. The continuously improved reimbursement policy and the massively reduced price of antiviral drugs through government negotiation and central procurement have increased treatment accessibility and affordability. However, due to the low rates of diagnosis and treatment, China still faces a large challenge in achieving the 2030 goal of lowering HBV-related mortality by 65%. A public health approach involving concerted efforts from the government, medical community, industry, and society as a whole would be necessary to increase the uptake of HBV tests and treatment to achieve the global goal of eliminating viral hepatitis as a public health threat by 2030.